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Summary  A  54-year-old  woman  visited  our  hospital  because  of  palpitation  and  dizziness.  Sys-
tolic ejection  murmur,  Levine  IV/VI,  was  heard  at  the  left  sternal  border  and  atrial  gallop  was
auscultated  at  apex.  Echocardiogram  demonstrated  diffuse  hypertrophy  of  the  left  ventricular
walls extending  to  the  apex.  The  left  ventricular  walls  increased  symmetrically;  the  septal  and
the posterior  wall  measured  approximately  26  mm  and  30  mm  in  thickness,  respectively.  Apical
two-chamber  views  revealed  a  narrow  outﬂow  of  the  left  ventricular  cavity  at  apex  with  a  dis-
tinct convergence  zone,  where  color  ﬂow  Doppler  imaging  showed  turbulent  jet  ﬂow  from  mid
to late  systole.  The  leukocyte  -galactosidase  A  activity  was  lower  than  normal.  Percutaneous
endomyocardial  biopsy  showed  speciﬁc  change  for  Fabry’s  disease  by  electron  microscopy.  On
cardiac catheterization,  mid-ventricular  resting  pressure  gradient  of  approximately  90  mmHg
was shown.  This  pressure  gradient  dramatically  disappeared  after  intravenous  administration  of
70 mg  of  cibenzoline.  We  describe  a  rare  case  of  Fabry’s  disease  that  revealed  diffuse  hypertro-
phy having  dynamic  obstruction  at  mid-left  ventricle,  like  mid-ventricular  obstruction,  and  the
administration  of  cibenzoline  had  beneﬁcial  effects  on  pressure  gradient  of  mid-left  ventricle.
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abry’s  disease  is  a  rare  inborn  X-linked  glycosphingolipid
torage  disorder  resulting  from  deﬁcient  activity  of  the
ysosomal  enzyme  -galactosidase  A  [1,2]. The  major  man-
festations  of  Fabry’s  disease  include  progressive  renal
ailure,  stroke,  and  cardiovascular  disease,  all  of  which
Published by Elsevier Ltd. All rights reserved.
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Figure  1  Two-dimensional  echocardiograms  showed  parasternal  long-axis  view  (A),  short-axis  view  at  the  papillary  muscle  level
(B) and  apical  four-chamber  view  (C).  Diffuse  and  symmetrical  hypertrophy  of  the  left  ventricular  walls  extending  to  the  apex  was
shown, the  ventricular  septum  and  the  posterior  wall  measured  approximately  26  mm  and  30  mm  in  thickness,  respectively.  M-mode
echocardiograms  of  mitral  valve  demonstrated  no  systolic  anterior  motion  (D).
c
d
a
h
e
a
(
montribute  to  morbidity  and  premature  death.  While  Fabry’s
isease  is  an  X-linked  recessive  disorder,  affected  women
re  increasingly  recognized  [3].  Although  left  ventricular
ypertrophy  (LVH)  is  a  major  cardiac  ﬁnding  of  Fabry’s  dis-
ase,  there  is  no  case  report  of  having  dynamic  obstruction
t  mid-left  ventricle  (LV),  like  mid-ventricular  obstruction
o
c
g
oMVO).  It  has  been  reported  that  the  class  Ia  antiarrhyth-
ic  drug,  cibenzoline,  has  favorable  effects  on  hypertrophic
bstructive  cardiomyopathy  (HOCM)  [4].  We  describe  a  rare
ase  of  MVO  that  occurred  in  hypertrophic  LV  of  heterozy-
ous  Fabry’s  disease  and  that  improved  after  administration
f  cibenzoline.
MVO  occurred  in  hypertrophic  LV  of  heterozygous  Fabry’s  disease  e135
Figure  2  Apical  two-chamber  views  revealed  a  narrow  outﬂow  of  the  left  ventricular  cavity  at  apex  with  a  distinct  convergence
zone, where  color  ﬂow  Doppler  imaging  showed  turbulent  jet  ﬂow  from  mid-LV  at  late  systole.  LV,  left  ventricle;  PM,  papillary
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smuscle; MV,  mitral  valve;  MR,  mitral  valve  regurgitation.
Case  report
A  54-year-old  woman  visited  our  hospital  because  of  palpi-
tation  and  dizziness.  Physical  examination  revealed  regular
pulse  of  96  beats/min  and  blood  pressure  146/100  mmHg.
Systolic  ejection  murmur,  Levine  IV/VI,  was  heard  at  the  left
sternal  border  and  atrial  gallop  was  auscultated  at  apex.  Two
years  previously,  she  was  diagnosed  with  cardiac  hypertro-
phy  at  another  hospital,  but  did  not  undergo  further  medical
examination.  Her  mother  was  already  dead,  the  cause  of
which  was  unknown.A  12-lead  electrocardiogram  showed  advanced  LVH  and
duration  of  QRS  complex  was  prolonged  to  162  ms.  Chest
radiogram  showed  cardiomegaly  (cardio-thoracic  ratio  of
68%)  without  pulmonary  congestion.
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Figure  3  Left  ventriculography  in  systole  showed  a  hyperkineti
(A). Hemodynamic  assessment  revealed  a  signiﬁcant  pressure  grad
110/78 mmHg)  (B).  Intra-ventricular  pressure  gradient  decreased  f
intravenous  administration  of  cibenzoline  (70  mg;  1.2  mg/kg)  (C).Echocardiogram  demonstrated  diffuse  hypertrophy  of  the
V  walls  extending  to  the  apex.  The  LV  walls  increased
ymmetrically;  the  septal  and  the  posterior  wall  measured
pproximately  26  mm  and  30  mm  in  thickness,  respectively.
owever,  systolic  anterior  motion  (SAM)  of  mitral  valve
as  not  shown  and  there  was  no  evidence  of  dynamic  LV
ract  (LVOT)  obstruction  (Fig.  1).  Apical  two-chamber  views
evealed  a  narrow  outﬂow  of  the  LV  cavity  at  apex  with  a
istinct  convergence  zone,  where  color  ﬂow  Doppler  imag-
ng  showed  turbulent  jet  ﬂow  from  mid  to  late  systole
Fig.  2).  Urinalysis  showed  proteinuria  and  red  blood  cell
edimentation.  Serum  creatinine  level  was  1.03  mg/dl  and
stimated  glomerular  ﬁltration  rate  was  44  ml/min/1.73  m2.
agnetic  resonance  imaging  of  the  brain  showed  multiple
acuna  infarctions.  B-type  natriuretic  peptide  increased  to
c  contraction  pattern  at  the  level  of  the  mid-left  ventricle
ient  of  91  mmHg  (left  ventricular  apex  201/21  mmHg,  aorta
rom  91  mmHg  to  near  0  mmHg  in  one  and  half  minutes  after
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Figure  4  Endomyocardial  biopsy  specimens  showed  hypertrophic  myocardial  cells  and  marked  sarcoplasmic  vacuolization
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thematoxylin—eosin  (A)  200×  (B)  400×) Electron  microscopy  o
nclusion body  with  lamellar  conﬁguration.  Scale  bar  indicates  
 high  level  of  2082.3  pg/ml  and  leukocyte  -galactosidase  A
ctivity  was  low,  28.0  nmol/mg  protein/hour  (normal  range
9.8—116.4  nmol/mg).
Because  she  required  precise  examination,  we  performed
ardiac  catheterization  with  written  informed  consent.
oronary  angiography  showed  no  narrowing  of  major  epi-
ardial  coronary  arteries  and  the  LV  wall  motion  was
yperkinetic  (Fig.  3).  Mid-ventricular  resting  pressure  gradi-
nt  of  approximately  90  mmHg  was  shown  during  pullback  of
he  retrograde  catheter  from  LV  apex  to  the  aorta  through
he  outﬂow  tract.  This  pressure  gradient  between  the  LV
pex  and  the  aorta  dramatically  disappeared  after  one  and
alf  minutes  of  intravenous  administration  of  70  mg  of  ciben-
oline  (Fig.  3).
Percutaneous  endomyocardial  biopsy  was  performed
rom  the  right  ventricle  and  the  myocardial  samples  with
ematoxylin—eosin  staining  showed  cell  hypertrophy  and
arked  sarcoplasmic  vacuolization.  Electron  microscopy
emonstrated  a  great  amount  of  intracytoplasmic  inclusion
ody  with  lamellar  conﬁguration  (Fig.  4),  which  were  char-
cteristic  ﬁndings  of  Fabry’s  disease.
iscussionardiac  manifestations  of  Fabry’s  disease  include  LVH,  valvu-
ar  insufﬁciency,  conduction  defects  and  coronary  artery
isease  [5].  Particularly,  LVH  is  a  comparatively  major  ﬁnd-
ng  in  patients  with  Fabry’s  disease  [6].  The  LVH  in  patients
l
F
r myocardial  cells  showed  a  great  amount  of  intracytoplasmic
 in  (C),  and  500  nm  in  (D).
ith  Fabry’s  disease  is  usually  symmetrical  [3,7]. While  a
ew  cases  with  pressure  gradient  of  LVOT  were  reported  [8],
here  was  no  case  having  dynamic  obstruction  at  mid-LV,
ike  MVO,  a  variant  type  of  hypertrophic  cardiomyopathy.  In
he  present  case,  there  was  systolic  mid-LV  cavity  narrowing
ormed  by  hypertrophic  papillary  muscle  and  intraventricu-
ar  septum,  resulting  in  marked  pressure  gradient  at  mid-LV.
Although  medical  therapy,  such  as  -blockers  and
alcium-channel  antagonists  have  been  widely  used  for
ymptomatic  patients  with  HOCM,  they  are  often  insufﬁ-
ient  to  improve  functional  disability  as  well  as  to  reduce
he  extent  of  the  outﬂow  tract  obstruction  and  to  improve
iastolic  ﬁlling.  The  class  Ia  antiarrhythmic  drug,  cibenzo-
ine,  possesses  a  certain  calcium  channel-blocking  property
y  the  decrease  in  the  intracellular  Ca2+ concentration
n  cardiac  myocytes  [9],  which  leads  to  a decrease  in  LV
yocardial  contractility.  Its  mechanism  contributes  to  the
ttenuation  of  the  LV  pressure  gradient  and  diastolic  func-
ion  in  HOCM,  including  cases  of  MVO  [10]. In  this  patient,
he  administration  of  cibenzoline  had  also  resulted  in  dra-
atic  improvement  of  intraventricular  obstruction.  From
his  fact,  we  speculate  that  cibenzoline  can  simply  have  a
eneﬁcial  effect  on  the  LV  pressure  gradient  with  hypercon-
ractility,  regardless  of  types  of  underlying  cardiac  disease,
hrough  not  only  its  negative  inotropic  effect  but  also  ame-
ioration  of  diastolic  dysfunction.
Previously,  there  has  been  no  effective  treatment  for
abry’s  disease,  other  than  palliative  care.  Recently  enzyme
eplacement  therapy  has  shown  the  safety  and  efﬁcacy  of
ease
[
[
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[MVO  occurred  in  hypertrophic  LV  of  heterozygous  Fabry’s  dis
treatment  in  patients  with  Fabry’s  disease  [11,12].  In  car-
diac  hypertrophy,  enzyme  replacement  therapy  has  shown
regression  of  the  LV  mass  and  LV  wall  thickness  [13]. The
degree  of  LVH  is  correlated  with  the  severity  of  myocardial
ﬁbrosis,  and  in  less  advanced  myocardial  ﬁbrosis,  enzyme
replacement  therapy  has  shown  more  beneﬁcial  effect  on
the  inhibition  of  cardiac  involvement  [13]. In  the  present
case,  marked  hypertrophy  was  observed,  compared  to  the
previous  Fabry’s  reports.  It  is  conceivable  that  such  marked
hypertrophy  is  irreversible  and  that  the  course  of  hypertro-
phy  at  this  stage  is  unresponsive  to  enzyme  replacement
therapy.  Nevertheless,  for  inhibition,  the  involvement  of  not
only  cardiovascular  system  but  other  organs,  this  therapy
should  be  started  as  soon  as  possible.
In  conclusion,  the  present  case  demonstrates  that  Fabry’s
disease  can  take  the  form  of  mid-ventricular  obstruction.
Moreover,  it  suggests  that  cibenzoline  may  be  useful  in  the
treatment  of  mid-ventricular  obstruction  caused  by  Fabry’s
disease  that  revealed  diffuse  LVH.
References
[1] Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL,
Laster L. Enzymatic defect in Fabry’s disease, ceramidetrihex-
osidase deﬁciency. N Engl J Med 1967;276:1163—7.
[2] Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW,
Krivit W. Fabry’s disease: enzymatic diagnosis of hemizygotes
and heterozygotes, alpha-galactosidase activities in plasma,
serum, urine, and leukocytes. J Lab Clin Med 1973;81:157—71.
[3] Kampmann C, Baehner F, Whybra C, Martin C, Wiethoff
CM, Ries M, Gal A, Beck M. Cardiac manifestations of
Anderson—Fabry disease in heterozygous females. J Am Coll
Cardiol 2002;40:1668—74.[4] Hamada M, Shigematsu Y, Ikeda S, Hara Y, Okayama H, Kodama
K, Ochi T, Hiwada K. Class Ia antiarrhythmic drug cibenzo-
line: a new approach to the medical treatment of hypertrophic
obstructive cardiomyopathy. Circulation 1997;96:1520—4. e137
[5] Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G,
Beck M, Mehta A, Elliott PM, European FOS Investigators.
Cardiac manifestations of Anderson—Fabry disease: results
from the international Fabry outcome survey. Eur Heart J
2007;28:1228—35.
[6] Kampmann C, Linhart A, Baehner F, Palecek T, Wiethoff CM,
Miebach E, Whybra C, Gal A, Bultas J, Beck M. Onset and
progression of the Anderson—Fabry disease related cardiomy-
opathy. Int J Cardiol 2008;130:367—73.
[7] Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M,
Yoshida A, Kuriyama M, Hayashibe H, Sakuraba H, Tanaka H. An
atypical variant of Fabry’s disease in men with left ventricular
hypertrophy. N Engl J Med 1995;333:288—93.
[8] Colucci WS, Lorell BH, Schoen FJ, Warhol MJ, Grossman W.
Hypertrophic obstructive cardiomyopathy due to Fabry’s dis-
ease. N Engl J Med 1982;307:926—8.
[9] Holck M, Osterrieder W. Inhibition of the myocardial Ca2+
inward current by the class I antiarrhythmic agent, cibenzoline.
Br J Pharmacol 1986;87:705—11.
10] Hamada M, Shigematsu Y, Inaba S, Aono J, Ikeda S, Watan-
abe K, Ogimoto A, Ohtsuka T, Hara Y, Higaki J. Antiarrhythmic
drug cibenzoline attenuates left ventricular pressure gradient
and improves transmitral Doppler ﬂow pattern in patients with
hypertrophic obstructive cardiomyopathy caused by midven-
tricular obstruction. Circ J 2005;69:940—5.
11] Schiffmann R, Kopp JB, Austin 3rd HA, Sabnis S, Moore DF,
Weibel T, Balow JE, Brady RO. Enzyme replacement ther-
apy in Fabry disease: a randomized controlled trial. JAMA
2001;285:2743—9.
12] Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S,
Caplan L, Linthorst GE, Desnick RJ, International Collaborative
Fabry Disease Study Group. Safety and efﬁcacy of recombinant
human alpha-galactosidase A — replacement therapy in Fabry’s
disease. N Engl J Med 2001;345:9—16.
13] Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Störk
S, Voelker W, Ertl G, Wanner C, Strotmann J. Long-term effects
of enzyme replacement therapy on Fabry cardiomyopathy: evi-
dence for a better outcome with early treatment. Circulation
2009;119:524—9.
